Doxorubicin hydrochloride
( DrugBank: Doxorubicin, Doxorubicin hydrochloride / KEGG DRUG: Doxorubicin hydrochloride, Doxorubicin, Doxorubicin hydrochloride, Doxorubicin )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 26 | HTLV-1-associated myelopathy | 2 |
| 34 | Neurofibromatosis | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 331 | Idiopathic multicentric castleman disease | 1 |
26. HTLV-1-associated myelopathy
Clinical trials : 32 / Drugs : 46 - (DrugBank : 27) / Drug target genes : 35 - Drug target pathways : 124
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
34. Neurofibromatosis
Clinical trials : 165 / Drugs : 189 - (DrugBank : 83) / Drug target genes : 93 - Drug target pathways : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
331. Idiopathic multicentric castleman disease
Clinical trials : 40 / Drugs : 45 - (DrugBank : 29) / Drug target genes : 43 - Drug target pathways : 163
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|